Release of testosterone from an osmotic pump tablet utilizing (SBE)7m-β-cyclodextrin as both a solubilizing and an osmotic pump agent

被引:65
作者
Okimoto, K
Rajewski, RA
Stella, VJ [1 ]
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[2] Fujisawa Pharmaceut Co Ltd, Osaka 532, Japan
[3] Univ Kansas, Ctr Drug Delivery Res, Lawrence, KS 66047 USA
关键词
cyclodextrin; osmotic pump; solubilization; controlled release; (SBE)(7m)-beta-CD;
D O I
10.1016/S0168-3659(98)00142-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A controlled porosity osmotic pump system for poorly water soluble drugs has been developed using sulfobutyl ether-beta-cyclodextrin sodium salt, (SBE)(7m)-beta-CD, which can act as both a solubilizing and an osmotic agent. The release of testosterone, a poorly water soluble drug (0.039 mg/ml at 37 degrees C), was evaluated using a new model device. The effect of (SBE)(7m)-beta-CD as the solubilizing and osmotic pump agent was compared with hydroxypropyl-beta-cyclodextrin (HP-beta-CD), a neutral cyclodextrin, and a sugar mixture (osmotic agent only). Testosterone release from the device was significantly faster with (SBE)(7m)-beta-CD than with HP-beta-CD or the sugar mixture. The solubility of testosterone in the device increased to 76.7 mg/ml through complexation with (SBE)(7m)-beta-CD in the imbibed water. it appears that testosterone release from the device in the presence of (SBE)(7m)-beta-CD was mainly due to osmotic pumping while for HP-beta-CD the major contribution appears to be due to diffusion. In the case of the sugar mixture, testosterone was poorly released, presumably due to the absence of a solubilizer. Therefore, it was concluded that (SBE)(7m)-beta-CD provides novel properties for the development of controlled-porosity osmotic pump tablets for poor solubility drugs. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 22 条
[1]  
[Anonymous], [No title captured], Patent No. [4,968,507, 4968507]
[2]  
CICHON R, 1991, PHARMAZIE, V46, P719
[3]  
Cortese R, 1982, US Patent, Patent No. [4327725, 4,327,725]
[4]  
ECKENHOFF B, 1987, PHARM TECHNOL JUN, P96
[5]   EFFECT OF SBE4-BETA-CD, A SULFOBUTYL ETHER BETA-CYCLODEXTRIN, ON THE STABILITY AND SOLUBILITY OF O-6-BENZYLGUANINE (NSC-637037) IN AQUEOUS-SOLUTIONS [J].
GORECKA, BA ;
SANZGIRI, YD ;
BINDRA, DS ;
STELLA, VJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 125 (01) :55-61
[6]   ASYMMETRIC-MEMBRANE TABLET COATINGS FOR OSMOTIC DRUG-DELIVERY [J].
HERBIG, SM ;
CARDINAL, JR ;
KORSMEYER, RW ;
SMITH, KL .
JOURNAL OF CONTROLLED RELEASE, 1995, 35 (2-3) :127-136
[7]  
Higuchi T., 1965, Interscience, New York, V4, P117
[8]   SOLUBILIZATION OF A TRIPEPTIDE HIV PROTEASE INHIBITOR USING A COMBINATION OF IONIZATION AND COMPLEXATION WITH CHEMICALLY-MODIFIED CYCLODEXTRINS [J].
JOHNSON, MD ;
HOESTEREY, BL ;
ANDERSON, BD .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (08) :1142-1146
[9]   THE SOLUBILITY-MODULATED OSMOTIC PUMP - INVITRO INVIVO RELEASE OF DILTIAZEM HYDROCHLORIDE [J].
MCCLELLAND, GA ;
SUTTON, SC ;
ENGLE, K ;
ZENTNER, GM .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :88-92
[10]   The interaction of charged and uncharged drugs with neutral (HP-beta-CD) and anionically charged (SBE7-beta-CD) beta-cyclodextrins [J].
Okimoto, K ;
Rajewski, RA ;
Uekama, K ;
Jona, JA ;
Stella, VJ .
PHARMACEUTICAL RESEARCH, 1996, 13 (02) :256-264